Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.
about
Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motifA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaLarge-scale pharmacological profiling of 3D tumor models of cancer cells.Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyA phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomibValidation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicityOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.Novel agents for the treatment of childhood acute leukemia.The 26S proteasome complex: an attractive target for cancer therapyPolymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell linesFV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.Inhibitors of the immunoproteasome: current status and future directionsCarfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.New proteasome inhibitors in myeloma.Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.Carfilzomib: a novel agent for multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Carfilzomib in multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Practical Approaches to the Management of Dual Refractory Multiple Myeloma.Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma.The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug TargetClinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study.Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.
P2860
Q27688108-6032BC14-5542-4A0C-8EF7-3B4EEA021388Q28067148-04E28A5F-118D-49A4-A0AD-DC2A594F5980Q30364972-F0B1E563-0136-471B-A9D4-1F433A837F7FQ31094748-D05402CC-18F8-4CF8-A8EB-FAE1BAA378B3Q33405119-32AB4476-7DA9-4DC9-95CA-80B3D9F78F48Q33405602-083F27D9-7A1A-44E3-B73F-EDBB274269FAQ33416105-71D87E16-7E82-483D-9E9E-74F963574397Q33710330-6C7291AA-8A8D-4745-B6EE-8EED840F4B22Q34317307-CC383398-C686-4548-9A5D-4E840299A255Q34473136-D9623F72-1DDE-487C-819A-F21ECA45FD49Q34788381-AF6233D9-5C08-468C-9016-89797E7A5F2EQ34893956-C618F06E-E6D8-45C4-BC11-5A208F07A4C4Q35192790-811E55FC-E481-4D4D-A2DE-50AE664F2877Q35624079-0192141A-F8B5-4B91-B194-358388356101Q36186214-4B512369-AC07-448B-BCFC-09E5C196D2ADQ36293871-7A7B3DEC-6050-4238-AAB7-40AD26FF2AF6Q36300784-C34B8DD3-2E1C-4F07-AA2C-81044CB42147Q36354644-C8850023-64FC-4325-B861-41F9801C660EQ36413676-4206015D-919F-46BD-BC9D-80FE651DF08CQ37058114-825C3E15-6579-493D-B291-3D1554FB1B80Q37199819-6AFF937A-F28A-4464-B729-A0FC4ED11799Q37292307-15552E7F-B974-49EE-8A1F-D74370E8446DQ38044986-6420370A-6607-4FAD-818B-CE70698426B8Q38052079-0E302CD2-4F64-4267-BE40-505215CB4C98Q38079578-1AB7B9C2-22D9-46F2-81E3-6764429F12D2Q38120066-81C96A2D-DC13-48A4-8A04-617A39C39CD2Q38120296-48838E6D-0DE5-4A73-824B-9A97C9899888Q38187476-EAE2567F-35C4-4DE7-BCB6-9A2A12B4034BQ38218209-2C5B58A8-FCEA-41B3-89AA-A50DC6883F1EQ38227506-51C624FE-861F-46AC-A44D-AF28BFCE4067Q38244558-8FD27D06-674B-4358-AAF4-B77DA95B824FQ38271032-969805FD-54BE-4289-A5FC-563FD19F2ABAQ38742700-252F93E9-C0A8-4624-B387-003C036CD1ABQ38964327-9694CBB0-CA04-4F32-84C6-4BC058FF98C8Q38989789-380FEDC9-53C1-45C5-917E-1F38B1D85547Q40083541-6D355EC2-4B84-4B9A-AB38-FF94BCF17D50Q41519882-0A04850C-7B96-4F7B-8696-5749DCB64F7AQ41531584-614F0C82-9BB3-47E1-90FC-C49CDC8A5E5FQ42281121-ED9EF1EC-F413-4D0A-8144-BF75EC985499Q43127820-BF60A77D-0945-40E8-BA5F-5F292601A232
P2860
Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Pharmacokinetics, pharmacodyna ...... retion of carfilzomib in rats.
@en
Pharmacokinetics, pharmacodyna ...... retion of carfilzomib in rats.
@nl
type
label
Pharmacokinetics, pharmacodyna ...... retion of carfilzomib in rats.
@en
Pharmacokinetics, pharmacodyna ...... retion of carfilzomib in rats.
@nl
prefLabel
Pharmacokinetics, pharmacodyna ...... retion of carfilzomib in rats.
@en
Pharmacokinetics, pharmacodyna ...... retion of carfilzomib in rats.
@nl
P2093
P356
P1476
Pharmacokinetics, pharmacodyna ...... retion of carfilzomib in rats.
@en
P2093
Christopher J Kirk
Christopher J Molineaux
Frances Zhao
Hansen Wong
Jinfu Yang
Jing Jiang
Mark K Bennett
Zhengping Wang
P304
P356
10.1124/DMD.111.039164
P577
2011-07-13T00:00:00Z